Article
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.
Cell reports - 28 Nov 2023
Zavitsanou Anastasia-Maria, Pillai Ray, Hao Yuan, Wu Warren L, Bartnicki Eric, Karakousi Triantafyllia, Rajalingam Sahith, Herrera Alberto, Karatza Angeliki, Rashidfarrokhi Ali, Solis Sabrina, Ciampricotti Metamia, Yeaton Anna H, Ivanova Ellie, Wohlhieter Corrin A, Buus Terkild B, Hayashi Makiko, Karadal-Ferrena Burcu, Pass Harvey I, Poirier John T, Rudin Charles M, Wong Kwok-Kin, Moreira Andre L, Khanna Kamal M, Tsirigos Aristotelis, Papagiannakopoulos Thales, Koralov Sergei B
Abstract excerpt
Lung cancer treatment has benefited greatly through advancements in immunotherapies. However, immunotherapy often fails in patients with specific mutations like KEAP1, which are frequently found in lung adenocarcinoma. We established an antigenic lung cancer model and used it to explore how Keap1 mutations remodel the tumor immune microenvironment. Using single-cell technology and depletion studies, we...
Topics
Join the communities discussing this publication.